Chronic Kidney Disease News and Research

Latest Chronic Kidney Disease News and Research

Updates on dietary benefits and dangers in kidney disease patients

Two studies presented during the American Society of Nephrology's Annual Kidney Week provide new information on dietary benefits and dangers in kidney disease patients.

11 Nov 2011

Aristolochic acid leads to kidney failure, upper urinary tract cancer

Aristolochic acid, a component of a plant used in herbal remedies since ancient times and still used in certain herbal medicines worldwide, leads to kidney failure and upper urinary tract cancer in individuals exposed to the toxin.

10 Nov 2011

MILV subsidiary acquires formula to restore proper kidney function

Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. announced that it has executed the formal closing documents and acquired the chronic kidney disease formula. This formula was developed to restore proper kidney function.

7 Nov 2011

HeRO graft device provides long-term AV access for hemodialysis patients

University Hospitals Case Medical Center physicians are utilizing a novel approach to solve a long standing problem for chronic kidney disease patients on hemodialysis.

5 Nov 2011

VA announces 13 new awards in 2010 Industry Innovation Competition

The Department of Veterans Affairs today announced 13 new awards in the agency's 2010 Industry Innovation Competition. The new projects will give VA an opportunity to evaluate new ways to enhance care and benefits for Veterans.

5 Nov 2011

Merck’s cholesterol lowering drug gets FDA panel’s vote

A health advisors’ panel have unanimously backed the use of Merck & Co's cholesterol-lowering drug Vytorin for preventing stroke and other heart problems in patients with chronic kidney disease, but only in those patients not yet on dialysis. The panel voted 16-0 during a meeting today in Silver Spring, Maryland.

3 Nov 2011

FDA EMDAC votes to recommend approval of Merck's VYTORIN for pre-dialysis CKD

Merck, known as MSD outside the United States and Canada, announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously voted to recommend approval of Merck's VYTORIN (ezetimibe/simvastatin) for use in patients with pre-dialysis chronic kidney disease.

3 Nov 2011

Hospitalized diabetic patients with acute kidney injury more likely to develop CKD

Findings from a recent University of Cincinnati (UC) and Cincinnati Department of Veterans Affairs (VA) Medical Center study show that multiple episodes of acute kidney injury during hospital stays for patients with diabetes are associated with a risk for developing chronic kidney disease.

2 Nov 2011

FDA's ODAC to review Affymax peginesatide NDA for treatment of CKD-associated anemia

Affymax, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for peginesatide proposed for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis on December 7, 2011 during the afternoon session.

24 Oct 2011

Americans on a sodium high: CDC report

A new study by federal government researchers shows that most Americans consume too much sodium, and new strategies and stronger efforts are needed to reduce the amount of dietary salt. Experts add that high levels of sodium consumption are associated with increased risk of high blood pressure, which can lead to heart disease and stroke.

20 Oct 2011

Data from Concert Pharmaceuticals' CTP-499 study to be presented at ASN Kidney Week 2011

Concert Pharmaceuticals, Inc. today announced that three abstracts relating to CTP-499, its clinical candidate for the potential treatment of diabetic nephropathy, have been accepted for poster presentations at the American Society of Nephrology's (ASN) Kidney Week 2011.

19 Oct 2011

Viewpoints: CLASS decision ends fear of government bailout; the strengths and failings of U.S. health care

The problem, as numerous experts warned at the time, was whether the program could be run, as the law required, in a way that made it financially solvent for at least 75 years. The difficulty with the CLASS Act was ensuring that premiums could be set low enough to attract widespread participation but high enough to pay tbenefits. The risk was that the program would attract the sickest participants, who thought they might need its protections, and thereby drive premium prices ever higher in a spiral of dysfunctionhe promised.

19 Oct 2011

Nephron Dx to develop more accurate diagnostic kit for early detection of diabetic CKD

A new spin-off company from the National University of Singapore (NUS), called Nephron Dx, has recently been set up to develop a more accurate diagnostic kit for the earlier detection of diabetic chronic kidney disease. Nephron Dx aims to enter the multi-billion dollar kidney disease diagnostic market by 2013.

18 Oct 2011

New research on link between APOL1 gene variants and kidney disease in African Americans

Compared to European Americans, African Americans are four to five times more likely to develop kidney failure. Also, family members of African Americans with kidney failure have an increased risk of developing kidney failure, which suggests that genetics may play a role in this skewed risk between races.

15 Oct 2011

Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease.

12 Oct 2011

Takeda, Affymax announce data from multiple studies of peginesatide on anemia

Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced data from multiple studies of peginesatide have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2011 taking place November 8-13, 2011 in Philadelphia, Pa.

11 Oct 2011

Dialysis patients with kidney failure more likely to develop serious complications from flu

For most people, the flu is a temporary setback that makes them feel under the weather for a week or two. For dialysis patients with kidney failure, however, the flu is a serious health threat that can lead to pneumonia and other life-threatening complications.

1 Oct 2011

Patients with chronic kidney disease do not need to undergo painful invasive procedures

Equations that estimate a patient's kidney function work as well as direct, invasive measurements, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

16 Sep 2011

Demand for kidney transplant and dialysis increases due to diabetes prevalence

A survey reveals that the need for kidney transplants and dialysis is expected to soar by 2020 mainly due to a rise in diabetics developing chronic kidney disease and needing treatment. The total number of Australians being treated for end-stage kidney disease is forecast to rise by up to 80 per cent to about 4300 in the coming decade. While the fact that Australia's population is ageing and growing means more people are likely to develop end-stage kidney disease, the number of diabetics with the condition is also on the rise.

15 Sep 2011

KAI enters KAI-4169 development and commercialization agreement with Ono

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the signing of an agreement with Ono Pharmaceutical Co., Ltd. for the development and commercialization in Japan of KAI-4169, KAI's lead product candidate.

15 Sep 2011